{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:12:40Z","timestamp":1788912760087,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08991"],"award-info":[{"award-number":["22K08991"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational study, we assessed soluble forms of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and PD-1 ligand 1 (PD-L1) using enzyme-linked immunosorbent assays; three TGF-\u03b2 isoforms were measured via multiplex assay in PE of patients with fibrinous pleuritis (FP) or MPM, to assess relationships between the levels of six molecules, clinicopathological characteristics, and efficacy of immune checkpoint inhibitors. Soluble forms of CTLA-4, PD-L1, PD-1, TGF-\u03b2<jats:sub>1<\/jats:sub>, TGF-\u03b2<jats:sub>2<\/jats:sub>, and TGF-\u03b2<jats:sub>3<\/jats:sub> were variably produced in PE of FP (n\u2009=\u200934) and MPM (n\u2009=\u200979); we found significant relationships between the six molecules and clinicopathological features. Although none of the three soluble immune checkpoint molecules showed diagnostic or prognostic effects in patients with MPM, TGF-\u03b2<jats:sub>2<\/jats:sub> level in PE is a useful differential diagnostic marker between FP and MPM. Both TGF-\u03b2<jats:sub>1<\/jats:sub> and TGF-\u03b2<jats:sub>3<\/jats:sub> levels are promising prognostic markers for MPM. Moreover, we found that higher baseline levels of PD-1 soluble forms predicted the response to anti-PD1 monotherapy. Our findings identify novel diagnostic, prognostic, and predictive biomarkers for anti-PD1 therapy in patients with MPM.<\/jats:p>","DOI":"10.1038\/s41598-024-66189-5","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T12:02:17Z","timestamp":1720612937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characterizing soluble immune checkpoint molecules and TGF-\u03b21,2,3 in pleural effusion of malignant pleural mesothelioma"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-1275","authenticated-orcid":false,"given":"Riki","family":"Okita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Senoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Mimura-Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6833-6075","authenticated-orcid":false,"given":"Eiji","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Inokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Aoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"66189_CR1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/JTO.0b013e31823f45c1","volume":"7","author":"DJ Pinato","year":"2012","unstructured":"Pinato, D. J. et al. Inflammation-based prognostic indices in malignant pleural mesothelioma. J. Thorac. Oncol. 7, 587\u2013594. https:\/\/doi.org\/10.1097\/JTO.0b013e31823f45c1 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"66189_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375\u2013386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8 (2021).","journal-title":"Lancet"},{"key":"66189_CR3","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690 (2012).","journal-title":"N. Engl. J. Med."},{"key":"66189_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in Advanced nonsquamous non-small-Cell Lung Cancer. N. Engl. J. Med. 373, 1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643 (2015).","journal-title":"N. Engl. J. Med."},{"key":"66189_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/imt-2020-0179","volume":"13","author":"FG Dall'Olio","year":"2021","unstructured":"Dall\u2019Olio, F. G. et al. Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: A meta-analysis. Immunotherapy 13, 257\u2013270. https:\/\/doi.org\/10.2217\/imt-2020-0179 (2021).","journal-title":"Immunotherapy"},{"key":"66189_CR6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/1759-7714.12815","volume":"9","author":"Q Tan","year":"2018","unstructured":"Tan, Q., Liu, S., Liang, C., Han, X. & Shi, Y. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis. Thorac. Cancer 9, 1220\u20131230. https:\/\/doi.org\/10.1111\/1759-7714.12815 (2018).","journal-title":"Thorac. Cancer"},{"key":"66189_CR7","doi-asserted-by":"publisher","first-page":"1039121","DOI":"10.3389\/fmolb.2022.1039121","volume":"9","author":"DC Guven","year":"2022","unstructured":"Guven, D. C. et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Mol. Biosci. 9, 1039121. https:\/\/doi.org\/10.3389\/fmolb.2022.1039121 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"66189_CR8","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1007\/s10238-023-01159-1","volume":"23","author":"V Mollica","year":"2023","unstructured":"Mollica, V. et al. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: The MOUSEION-06 study. Clin. Exp. Med. 23, 5039\u20135049. https:\/\/doi.org\/10.1007\/s10238-023-01159-1 (2023).","journal-title":"Clin. Exp. Med."},{"key":"66189_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550. https:\/\/doi.org\/10.1038\/s41591-018-0014-x (2018).","journal-title":"Nat. Med."},{"key":"66189_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571. https:\/\/doi.org\/10.1038\/nature13954 (2014).","journal-title":"Nature"},{"key":"66189_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121071","volume":"10","author":"S Cedr\u00e9s","year":"2015","unstructured":"Cedr\u00e9s, S. et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE. 10, e0121071. https:\/\/doi.org\/10.1371\/journal.pone.0121071 (2015).","journal-title":"PLoS ONE."},{"key":"66189_CR12","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","volume":"12","author":"SC Kao","year":"2017","unstructured":"Kao, S. C. et al. Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. J. Thorac. Oncol. 12, 1421\u20131433. https:\/\/doi.org\/10.1016\/j.jtho.2017.05.024 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"66189_CR13","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s11033-019-04715-9","volume":"46","author":"N Sobhani","year":"2019","unstructured":"Sobhani, N. et al. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma. Mol. Biol. Rep. 46, 2713\u20132720. https:\/\/doi.org\/10.1007\/s11033-019-04715-9 (2019).","journal-title":"Mol. Biol. Rep."},{"key":"66189_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00262-022-03292-4","volume":"72","author":"R Okita","year":"2023","unstructured":"Okita, R. et al. Effects of tumor-infiltrating CD8+ T cells, PD1\/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy. Cancer Immunol. Immunother. 72, 865\u2013879. https:\/\/doi.org\/10.1007\/s00262-022-03292-4 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"66189_CR15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00262-016-1844-3","volume":"65","author":"S Roncella","year":"2016","unstructured":"Roncella, S. et al. CTLA-4 in mesothelioma patients: Tissue expression, body fluid levels and possible relevance as a prognostic factor. Cancer Immunol. Immunother. 65, 909\u2013917. https:\/\/doi.org\/10.1007\/s00262-016-1844-3 (2016).","journal-title":"Cancer Immunol. Immunother."},{"key":"66189_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00432-020-03457-7","volume":"147","author":"R Carosio","year":"2021","unstructured":"Carosio, R. et al. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: Potential implications in the immune response and prognosis. J. Cancer Res. Clin. Oncol. 147, 459\u2013468. https:\/\/doi.org\/10.1007\/s00432-020-03457-7 (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"66189_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2249.1994.tb06144.x","volume":"98","author":"J Maeda","year":"1994","unstructured":"Maeda, J. et al. Transforming growth factor-beta 1 (TGF-beta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer. Clin. Exp. Immunol. 98, 319\u2013322. https:\/\/doi.org\/10.1111\/j.1365-2249.1994.tb06144.x (1994).","journal-title":"Clin. Exp. Immunol."},{"key":"66189_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.lungcan.2019.11.013","volume":"139","author":"P Stockhammer","year":"2020","unstructured":"Stockhammer, P. et al. Detection of TGF-beta in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Lung Cancer 139, 124\u2013132. https:\/\/doi.org\/10.1016\/j.lungcan.2019.11.013 (2020).","journal-title":"Lung Cancer"},{"key":"66189_CR19","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrc1926","volume":"6","author":"B Bierie","year":"2006","unstructured":"Bierie, B. & Moses, H. L. Tumour microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506\u2013520. https:\/\/doi.org\/10.1038\/nrc1926 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"66189_CR20","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9, J. & Sheppard, D. TGF-beta signaling in health and disease. Cell. 186, 4007\u20134037. https:\/\/doi.org\/10.1016\/j.cell.2023.07.036 (2023).","journal-title":"Cell."},{"key":"66189_CR21","doi-asserted-by":"publisher","first-page":"20533","DOI":"10.1016\/S0021-9258(17)30535-5","volume":"265","author":"S Cheifetz","year":"1990","unstructured":"Cheifetz, S. et al. Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J. Biol. Chem. 265, 20533\u201320538 (1990).","journal-title":"J. Biol. Chem."},{"key":"66189_CR22","volume-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","author":"WD Travis","year":"2015","unstructured":"Travis, W. D., International Agency for Research on C. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (International Agency for Research on Cancer, 2015)."},{"key":"66189_CR23","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","volume":"11","author":"AK Nowak","year":"2016","unstructured":"Nowak, A. K. et al. The IASLC mesothelioma staging project: Proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J. Thorac. Oncol. 11, 2089\u20132099. https:\/\/doi.org\/10.1016\/j.jtho.2016.08.147 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"66189_CR24","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.jtho.2016.09.121","volume":"11","author":"D Rice","year":"2016","unstructured":"Rice, D. et al. The IASLC Mesothelioma Staging Project: Proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J. Thorac. Oncol. 11, 2100\u20132111. https:\/\/doi.org\/10.1016\/j.jtho.2016.09.121 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"66189_CR25","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","volume":"11","author":"VW Rusch","year":"2016","unstructured":"Rusch, V. W. et al. The IASLC mesothelioma staging project: Proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J. Thorac. Oncol. 11, 2112\u20132119. https:\/\/doi.org\/10.1016\/j.jtho.2016.09.124 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"66189_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","volume":"11","author":"R Shrestha","year":"2019","unstructured":"Shrestha, R. et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med. 11, 8. https:\/\/doi.org\/10.1186\/s13073-019-0620-3 (2019).","journal-title":"Genome Med."},{"key":"66189_CR27","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/s0003-4975(99)01038-3","volume":"68","author":"VW Rusch","year":"1999","unstructured":"Rusch, V. W. & Venkatraman, E. S. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann. Thorac. Surg. 68, 1799\u20131804. https:\/\/doi.org\/10.1016\/s0003-4975(99)01038-3 (1999).","journal-title":"Ann. Thorac. Surg."},{"key":"66189_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1510\/icvts.2007.166322","volume":"7","author":"M Okada","year":"2008","unstructured":"Okada, M. et al. Radical surgery for malignant pleural mesothelioma: Results and prognosis. Interact. Cardiovasc. Thorac. Surg. 7, 102\u2013106. https:\/\/doi.org\/10.1510\/icvts.2007.166322 (2008).","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"66189_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne, M. J. & Nowak, A. K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann. Oncol. 15, 257\u2013260. https:\/\/doi.org\/10.1093\/annonc\/mdh059 (2004).","journal-title":"Ann. Oncol."},{"key":"66189_CR30","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","volume":"16","author":"DE Jensen","year":"1998","unstructured":"Jensen, D. E. et al. BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 ring finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16, 1097\u20131112. https:\/\/doi.org\/10.1038\/sj.onc.1201861 (1998).","journal-title":"Oncogene"},{"key":"66189_CR31","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jclinpath-2016-203866","volume":"69","author":"A Wang","year":"2016","unstructured":"Wang, A., Papneja, A., Hyrcza, M., Al-Habeeb, A. & Ghazarian, D. Gene of the month: BAP1. J. Clin. Pathol. 69, 750\u2013753. https:\/\/doi.org\/10.1136\/jclinpath-2016-203866 (2016).","journal-title":"J. Clin. Pathol."},{"key":"66189_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102091","volume":"90","author":"BH Louie","year":"2020","unstructured":"Louie, B. H. & Kurzrock, R. BAP1: Not just a BRCA1-associated protein. Cancer Treat. Rev. 90, 102091. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102091 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"66189_CR33","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","volume":"11","author":"L Righi","year":"2016","unstructured":"Righi, L. et al. BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: A large retrospective study. J. Thorac. Oncol. 11, 2006\u20132017. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.020 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"66189_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13073-019-0631-0","volume":"11","author":"M Ladanyi","year":"2019","unstructured":"Ladanyi, M., Sanchez Vega, F. & Zauderer, M. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. Genome Med. 11, 18. https:\/\/doi.org\/10.1186\/s13073-019-0631-0 (2019).","journal-title":"Genome Med."},{"key":"66189_CR35","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548. https:\/\/doi.org\/10.1038\/nature25501 (2018).","journal-title":"Nature"},{"key":"66189_CR36","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1073\/pnas.90.2.770","volume":"90","author":"AB Kulkarni","year":"1993","unstructured":"Kulkarni, A. B. et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 90, 770\u2013774. https:\/\/doi.org\/10.1073\/pnas.90.2.770 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66189_CR37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/ng1295-409","volume":"11","author":"G Proetzel","year":"1995","unstructured":"Proetzel, G. et al. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat. Genet. 11, 409\u2013414. https:\/\/doi.org\/10.1038\/ng1295-409 (1995).","journal-title":"Nat. Genet."},{"key":"66189_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/toxsci\/kfaa024","volume":"175","author":"MS Mitra","year":"2020","unstructured":"Mitra, M. S. et al. A potent pan-TGFbeta neutralizing monoclonal antibody elicits cardiovascular toxicity in mice and cynomolgus monkeys. Toxicol. Sci. 175, 24\u201334. https:\/\/doi.org\/10.1093\/toxsci\/kfaa024 (2020).","journal-title":"Toxicol. Sci."},{"key":"66189_CR39","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdx314","volume":"28","author":"I Huber-Ruano","year":"2017","unstructured":"Huber-Ruano, I. et al. An antisense oligonucleotide targeting TGF-beta2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages. Ann. Oncol. 28, 2278\u20132285. https:\/\/doi.org\/10.1093\/annonc\/mdx314 (2017).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66189-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66189-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66189-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T16:04:25Z","timestamp":1720886665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66189-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["66189"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-66189-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Keisuke Aoe has received grants and personal fees from Ono Pharmaceutical, Bristol-Myers Squibb, and AstraZeneca, and grants from Eli Lilly, Novartis, MSD, Pfizer, and Sanofi. The remaining authors declare no conflict of interest. All the funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15947"}}